Physician profile
Marvin M Baula
NPI 1104156819
$17,477.08
in general payments reported to CMS, 2019-2025
24 companies · $5,732 in 2025
The $5,732 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2021: $116 · 2022: $2,993 · 2023: $3,558 · 2024: $4,381 · 2025: $5,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,554.14 |
| Education | $117.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,235.09 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Axsome Therapeutics, INC. | $2,002.79 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $1,695.87 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,631.77 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $1,480.50 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,371.22 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,348.72 | 2019-2025 | Fanapt, Hetlioz, Ponvory |
| Lundbeck LLC | $1,055.67 | 2021-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $974.66 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $965.43 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $874.07 | 2019-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $407.30 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $358.75 | 2022 | |
| Almatica Pharma LLC | $300.83 | 2022-2024 | Loreev Xr, Gralise |
| Corium, LLC | $189.33 | 2022-2024 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $181.37 | 2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $168.01 | 2022-2024 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $92.17 | 2023-2024 | |
| Ironshore Pharmaceuticals INC. | $35.33 | 2022-2023 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $31.21 | 2022 | |
| Janssen Biotech, INC. | $23.22 | 2025 | Tremfya |
| Sage Therapeutics, LLC | $21.70 | 2024 | |
| Braeburn INC. | $18.31 | 2025 | Brixadi |
| Merck Sharp & Dohme LLC | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Baula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.